Zobrazeno 1 - 10 of 29 pro vyhledávání: '"Kai Shibata"'
1
Akademický článek
Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: Post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations.
Autor: Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi, Mika Ishii
Publikováno v: PLoS ONE, Vol 16, Iss 7, p e0253513 (2021)
A post-marketing study was performed on all patients who had started treatment with iguratimod, a conventional synthetic disease-modifying antirheumatic drug approved in Japan. During the study period, various safety measures were implemented to redu
Externí odkaz: https://doaj.org/article/3a0911d7be8740fdbb701f6d214dc9fb
Zobrazit plný text záznamu
2
Prevalence, incidence, and medications of narcolepsy in Japan: a descriptive observational study using a health insurance claims database
Autor: Aya Imanishi, Yuta Kamada, Kai Shibata, Yukinori Sakata, Hiroaki Munakata, Mika Ishii
Publikováno v: Sleep and Biological Rhythms. 20:585-594
The objectives of this study were to describe prevalence, incidence, and medications among patients who were diagnosed with narcolepsy in Japan using a claims database. Patients diagnosed with narcolepsy were identified from January 2010 to December
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ffbf6fdd7e9a2ea9a591d31ec7039dd
https://doi.org/10.1007/s41105-022-00406-4
Zobrazit plný text záznamu
5
Investigation of the predictors of the response to Iguratimod therapy: A post-hoc analysis of post-marketing surveillance study
Autor: Mika Ishii, Kai Shibata, Satoshi Ikeuchi, Naoki Ishiguro, Akiko Yoshimura
Publikováno v: Modern Rheumatology. 30:626-632
Objectives: The treatment response according to patient disease activity during Iguratimod therapy for rheumatoid arthritis has not been sufficiently assessed. A post-hoc analysis of post-marketing surveillance was performed. The treatment effect was
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da07d312bf7e2ba2365bc46d54fe90aa
https://doi.org/10.1080/14397595.2019.1649110
Zobrazit plný text záznamu
6
Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: Post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations
Autor: Akiko Yoshimura, Satoshi Ikeuchi, Mika Ishii, Kai Shibata
Publikováno v: PLoS ONE
PLoS ONE, Vol 16, Iss 7, p e0253513 (2021)
A post-marketing study was performed on all patients who had started treatment with iguratimod, a conventional synthetic disease-modifying antirheumatic drug approved in Japan. During the study period, various safety measures were implemented to redu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a32aa3bd669f2dd398cce83d663c5a
https://pubmed.ncbi.nlm.nih.gov/34329291
Zobrazit plný text záznamu
8
Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction: Post-hoc analysis of an all-case post-marketing surveillance study of iguratimod
Autor: Satoshi Ikeuchi, Mika Ishii, Naoki Ishiguro, Akiko Yoshimura, Kai Shibata
Objectives: Adverse drug reactions (ADRs) related to liver dysfunction are a common problem in patients with rheumatoid arthritis (RA) receiving iguratimod, but which patient subgroups go on to discontinue iguratimod treatment is unclear. A post-hoc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac53b62567c15b32edf3f014036bf33
Zobrazit plný text záznamu
9
Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study
Autor: Kai Shibata, Hiromasa Inoue, Masakazu Ichinose, Hideaki Miyagishi, Koichiro Tatsumi, Yoshinosuke Fukuchi, Yukinori Sakata, Yasuhiro Marukawa
Publikováno v: International Journal of Chronic Obstructive Pulmonary Disease
Yoshinosuke Fukuchi,1 Koichiro Tatsumi,2 Hiromasa Inoue,3 Yukinori Sakata,4 Kai Shibata,4 Hideaki Miyagishi,4 Yasuhiro Marukawa,4 Masakazu Ichinose5 1Department of Respiratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, 2Depart
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6ba789d188c1270368c2a0d5c5a9dbb
http://europepmc.org/articles/PMC4846053
Zobrazit plný text záznamu
10
Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study
Autor: Toshihisa Arai, Hiroyuki Ohbayashi, Kai Shibata, Yasuhiro Setoguchi, Yoshinosuke Fukuchi, Yukinori Sakata
Publikováno v: Pulmonary Pharmacology & Therapeutics. 37:73-80
Background Mucolytic agents are often used in Japan to ease excessive mucus production in patients with chronic obstructive pulmonary disease (COPD) or bronchial asthma (BA); the treatment ameliorates dyspnea and improves quality of life (QOL). Aim E
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fce59161a7971a144a4d903a33fee55
https://doi.org/10.1016/j.pupt.2016.03.001
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje